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Abstract 
 
A recent World Health Organisation study conducted in 26 countries found substantial 
disagreement in the prescribing information available in those countries, as well as 
significant disparity between brands within the same country. This appears to be a 
common experience in other countries. This may mislead prescribers, patients and those 
comparing drug-use patterns across countries, and have serious safety implications. 
 
This study was carried out to investigate the variability of prescribing information 
currently available within South Africa, comparing generic and originator brands. It also 
investigated the extent of variability between the Standardised Package Insert (SPI) 
mandated by the Medicines Control Council, versus internationally approved prescribing 
information for given drug substances. 
 
Five drug substances were selected that are widely used in South Africa. The package 
inserts of the originator product were compared in terms of the indications, dosage, 
cautions, side-effects and drug interactions versus five generic brands of each drug 
substance registered in South Africa, using a comprehensive method adapted from the 
WHO study. The SPI was also compared against the South African originator brand 
package insert and those approved in four international MCC Reference Countries (ie. 
USA, EU, Canada & Australia) for each drug substance. 
 
Substantial disagreement was found between the originator and generic products for each 
drug substance, which may be due, in part, to the absence of a mandatory periodic 
updating requirement for package inserts in the post-registration phase in South Africa. 
This may result in divergence between materials from companies that voluntarily submit 
safety updates over the life of the product, and those that do not.  
 
There was also substantial disagreement between the SPI and the originator and 
international reference country materials. The reason is less simple to explain. The SPI 
project is in its early stages, and requires validation to ensure that the texts are in fact, 
entirely in line with latest best clinical practice and with the reference countries with 
which MCC aligns itself. 
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 These findings are comparable with those found in international WHO study. 
 
Regulatory authorities have key responsibility in ensuring that prescribing information is 
current and consistent across originator, generic and international materials.  
 
It is recommended that the MCC implement a mandatory updating requirement for all 
registered medicines with specified timelines. Secondly, a validation step should be 
introduced in the MCC SPI project to ensure consistency with international materials. 
Additional recommendations are made to improve the quality and practicality of 
prescribing information to ensure that it remains relevant in the South African and 
regional context. 
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